the importance risk stratification to enable risk-adapted therapy in mds & cmml
Published 1 year ago • 62 plays • Length 1:18Download video MP4
Download video MP3
Similar videos
-
0:58
risk stratification in mds
-
3:57
validation of the ipss-m risk stratification system in mds
-
3:24
improving risk stratification in all with risk scores & genomic studies to personalize therapy
-
1:50
considerations for risk-adapted therapy in lower-risk mds
-
1:40
mds 2023 highlights: classification and risk stratification systems & progression from ch to mds
-
3:59
the importance of accurately defining high-risk myeloma and current risk stratification systems
-
2:45
an insight into clinical risk factors for progression in mpns
-
1:11
an update to the risk stratification of mgus, smm, and multiple myeloma
-
3:27
characterization of the microbial resistome in a prospective trial of cbm588 in mrcc
-
30:10
diagnosis and risk stratification
-
2:41
an overview of the latest advances in hematology
-
2:03
aml risk stratification
-
1:57
using molecular abnormalities for risk stratification in multiple myeloma at the time of diagnosis
-
6:04
relevance of ipss-r for risk stratification in patients with mds who undergo sct
-
5:14
what is risk stratification?
-
2:02
unmet needs in high-risk mds and future therapeutic strategies
-
4:02
the benefits of gvhd risk stratification
-
3:23
progression risk stratification of asymptomatic wm
-
2:25
novel ai model for personalized risk stratification & treatment in newly diagnosed multiple myeloma
-
4:51
risk stratification & treatment of multiple myeloma precursor conditions
-
2:07
redefining risk stratification in multiple myeloma
-
11:53
the optimal treatment of lower risk mds